Segment Information (Tables)

3 Months Ended

Mar. 31, 2024

Segment Information

Summary of results of operations by segment

(In thousands)			Contract		Corporate		Total
Three Months Ended March 31, 2024	Therapeutics		Research		and Other		Company
Revenue from external customers	$	1,741	$	657	$	—	$	2,398
Intercompany revenue		—		3,666		(3,666)		—
Cost of revenue		—		4,024		(3,432)		592
Research and development		8,760		—		(233)		8,527
General and administrative		—		1,108		4,742		5,850
Licensing		1,031		—		—		1,031
Revaluation of contingent consideration		2,800		—		—		2,800
Restructuring expense		1,318		217		994		2,529
Loss from operations	$	(12,168)	$	(1,026)	$	(5,737)	$	(18,931)
(In thousands)			Contract		Corporate		Total
Three Months Ended March 31, 2023	Therapeutics		Research		and Other		Company
Revenue from external customers	$	1,638	$	890	$	—	$	2,528
Intercompany revenue		—		4,011		(4,011)		—
Cost of revenue		—		4,547		(3,739)		808
Research and development		22,859		—		(272)		22,587
General and administrative		—		1,062		7,728		8,790
Licensing		1,061		—		—		1,061
Revaluation of contingent consideration		(800)		—		—		(800)
Loss from operations	$	(21,482)	$	(708)	$	(7,728)	$	(29,918)